Lycia Therapeutics initiates coverage with buy rating from TD Cowen
LYCA•TD Cowen initiated coverage of Lycia Therapeutics with a buy rating.
Related News

US dollar hits 19-month peak on Fed hike bets, while NZ dollar slumps
SPY•

Shares slide on tech weakness ahead of Nvidia earnings
NVDA•

CG Oncology target price raised to $91 from $84 by Wedbush
CGON•

US releases details of Megaspeed probe, says investigation began in 2024
NVDA•

BYD relies on local supply chains in some overseas operations including in Thailand
BYDDF•